Biopharma Dealmaking Shifts to 'Multi-Track' Strategies Amid Market Complexity

The Multi-Track Reality

"This $65 billion year-to-date M&A swamp has meant a lot of investors with a significant amount of capital to redeploy, and they are eager to do that," said Anamaria Sudarov, managing director for healthcare investment banking at Wells Fargo. The liquidity is forcing a structural reset across the sector.

Three mechanics confirm the shift:

• Process compression: Companies file for IPO on Friday, announce M&A the following Monday. What once took quarters now runs in days, per multiple panelists.

• Banker agnosticism: M&A-only bankers now represent biotechs across all deal structures. "It's 'Let's get a deal done,'" said Casarine Chong, general counsel for R&D and business development at CSL. Deal type is no longer the constraint—closing is.

• Early-stage adoption: Rachel Lane, SVP of Business Development at Xaira Therapeutics, noted that preclinical companies now leverage platform assets to pre-negotiate future M&A. Johnson & Johnson's $1 billion acquisition of Firefly Bio was cited as the working template.

Where Leverage Sits Now

Power has migrated from Big Pharma to biotechs with viable assets and credible data packages. Deepa Talpade, head of business development and licensing for oncology at Bayer, was direct: "A large amount of biotechs will be talking to you on a deal front, and also talking about, 'I'm raising my next series, whichever gives me the best bang for my buck.'"

The pressure on Big Pharma is now operational, not strategic. Chong's warning: license collaborations must be structured to preserve M&A optionality, not foreclose it. The window for exclusive negotiation has narrowed. Chong's implicit message to pharma BD teams: "You've got a limited period of time to execute on this deal, otherwise we've got both IPO funding or an M&A on the horizon as well."

The Real Constraint

Bandwidth. Maha Radhakrishnan, executive partner in private equity at Sofinnova Investments, identified the actual bottleneck: "It comes back to resources. It comes back to are people able to go on this dual or triple from a standpoint of being able to manage multiple priorities, but still keep on track."

Multi-track requires parallel senior bankers, counsel, and IR capacity running simultaneously. Each track demands its own diligence package, disclosure protocol, and legal review. The biotechs that close in 2026 will be the ones that funded this infrastructure before the rush—not the ones with the cleanest preclinical data alone. Scientific edge without execution capacity equals missed windows.

The verdict: multi-track is baseline. Dual-track is legacy. Single-track is a distress signal.